Cardiovascular disease in rheumatoid arthritis: A step forward

Current Opinion in Rheumatology

Volumn 22, Issue 3, 2010, Pages 342-347

  Myasoedova, Elena ^a   Gabriel, Sherine E ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cardiovascular disease; Cardiovascular risk management; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT;

ALGORITHM; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISEASE MARKER; DRUG MEGADOSE; DRUG SAFETY; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; HUMAN; INFLAMMATION; LOW DRUG DOSE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHEUMATOID ARTHRITIS; RISK MANAGEMENT; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BLOOD VESSELS; CARDIOVASCULAR DISEASES; EARLY DIAGNOSIS; EVIDENCE-BASED MEDICINE; HUMANS; INFLAMMATION; RISK ASSESSMENT;

EID: 77950311294     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3283379b91     Document Type: Review

References (50)

1. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59:1690-1697.
2. Wolfe F, Michaud K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. Arthritis Rheum 2008; 58:2612-2621.
3. Davis JM 3rd, Roger VL, Crowson CS, et al. The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population. Arthritis Rheum 2008; 58:2603-2611.
4. Kao AH, Wasko MC, Krishnaswami S, et al. C-reactive protein and coronary artery calcium in asymptomatic women with systemic lupus erythematosus or rheumatoid arthritis. Am J Cardiol 2008; 102:755-760.
5. Rho YH, Chung CP, Oeser A, et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2009; 61:1580-1585.
6. Liang KP, Kremers HM, Crowson CS, et al. Autoantibodies and the risk of cardiovascular events. J Rheumatol 2009; 36:2462-2469.
7. Provan SA, Angel K, Odegard S, et al. The association between disease activity and NT-proBNP in 238 patients with rheumatoid arthritis: a 10-year longitudinal study. Arthritis Res Ther 2008; 10:R70.
8. van Halm VP, Peters MJ, Voskuyl AE, et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis 2009; 68:1395-1400.
9. Peters MJ, van Halm VP, Voskuyl AE, et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 2009; 61:1571-1579.
10. Yavasoglu I, Senturk T, Onbasili A. Diastolic dysfunction in rheumatoid arthritis and duration of disease. Rheumatol Int 2008; 29:113-114.
11. Gonzalez A, Maradit Kremers H, Crowson CS, et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in nonrheumatoid arthritis patients? Ann Rheum Dis 2008; 67:64-69.
12. Book C, Karlsson MK, Akesson K, Jacobsson LT. Early rheumatoid arthritis and body composition. Rheumatology (Oxford) 2009; 48:1128-1132.
13. Giles JT, Ling SM, Ferrucci L, et al. Abnormal body composition pheno-types in older rheumatoid arthritis patients: association with disease characteristics and pharmacotherapies. Arthritis Rheum 2008; 59:807-815.
14. Elkan AC, Engvall IL, Cederholm T, Hafstrom I. Rheumatoid cachexia, central obesity and malnutrition in patients with low-active rheumatoid arthritis: feasibility of anthropometry, Mini Nutritional Assessment and body composition techniques. Eur J Nutr 2009; 48:315-322.
15. Panoulas VF, Toms TE, Metsios GS, et al. Target organ damage in patients with rheumatoid arthritis: The role of blood pressure and heart rate. Atherosclerosis 2009 [Epub ahead of print]
16. Corrao S, Scaglione R, Calvo L, Licata G. A meta-analysis of the effect size of rheumatoid arthritis on left ventricular mass: comment on the article by Rudominer et al. Arthritis Rheum 2009; 60:2851-2852.
17. Garćia-Gomez C, Nolla JM, Valverde J, et al. Conventional lipid profile and lipoprotein(a) concentrations in treated patients with rheumatoid arthritis. J Rheumatol 2009; 36:1365-1370.
18. Rho YH, Oeser A, Chung CP, et al. Drugs used in the treatment of rheumatoid arthritis: relationship between current use and cardiovascular risk factors. Arch Drug Inf 2009; 2:34-40.
19. Rizzo M, Spinas GA, Cesur M, et al. Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-näive patients with early rheumatoid arthritis. Atherosclerosis 2009; 207:502-506.
20. Garćia-Gomez C, Nolla JM, Valverde J, etal. High HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy. Eur J Clin Invest 2008; 38:686-692.
21. Myasoedova E, Crowson CS, Maradit-Kremers H, et al. Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis 2009 [Epub ahead of print].
22. Kremers HM, Crowson CS, Therneau TM, et al. High ten-year risk of cardio-vascular disease in newlydiagnosed rheumatoid arthritis patients: a population-based cohort study. Arthritis Rheum 2008; 58:2268-2274.
23. Jick SS, Choi H, Li L, et al. Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis. Ann Rheum Dis 2009; 68:546-551.
24. Giles JT, Szklo M, Post W, et al. Coronary arterial calcification in rheumatoid arthritis: comparison with the Multi-Ethnic Study of Atherosclerosis. Arthritis Res Ther 2009; 11:R36.
25. Gonzalez-Juanatey C, Llorca J, Martin J, Gonzalez-Gay MA. Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis. Semin Arthritis Rheum 2009; 38:366-371.
26. Galarraga B, Khan F, Kumar P, et al. Etanercept improves inflammation-associated arterial stiffness in rheumatoid arthritis. Rheumatology (Oxford) 2009; 48:1418-1423.
27. Sidiropoulos PI, Siakka P, Pagonidis K, et al. Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients. Scand J Rheumatol 2009; 38:6-10.
28. Kerekes G, Soltesz P, Der H, et al. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol 2009; 28:705-710.
29. Farragher TM, Goodson NJ, Naseem H, et al. Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum 2008; 58:359-369.
30. Gonzalez-Gay MA, Gonzalez-Juanatey C, Llorca J, et al. Contribution of HLA-DRB1 shared epitope alleles and chronic inflammation to the increased incidence of cardiovascular disease in rheumatoid arthritis: comment on the article by Farragher et al. Arthritis Rheum 2008; 58:2584; author reply 2584-2585 No abstract available.
31. Panoulas VF, Nikas SN, Smith JP, et al. Lymphotoxin 252AG polymorphism is common and associates with myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67:1550-1556.
32. Panoulas VF, Stavropoulos-Kalinoglou A, Metsios GS, et al. Association of interleukin-6 (IL-6)-174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking. Atherosclerosis 2009; 204:178-183.
33. Lin E, Freedman JE, Beaulieu LM. Innate immunity and toll-like receptor antagonists: a potential role in the treatment of cardiovascular diseases. Cardiovasc Ther 2009; 27:117-123.
34. Egan CG, Caporali F, Garcia-Gonzalez E, et al. Endothelial progenitor cells and colony-forming units in rheumatoid arthritis: association with clinical characteristics. Rheumatology (Oxford) 2008; 47:1484-1488.
35. Gonzalez-Gay MA, Llorca J, Garcia-Unzueta MT, et al. High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis. Clin Exp Rheumatol 2008; 26:596-603.
36. Graf J, Scherzer R, Grunfeld C, Imboden J. Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis. PLoS One 2009; 4:e6242.
37. Reiss AB, Carsons SE, Anwar K, et al. Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum 2008; 58:3675-3683.
38. Naranjo A, Sokka T, Descalzo MA, et al., QUEST-RA Group. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008; 10:R30.
39. Listing J, Strangfeld A, Kekow J, et al. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum 2008; 58:667-677.
40. Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scien-tific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost 2009; 7 (Suppl 1):332-339.
41. van Tuyl LH, Boers M, Lems WF, et al. Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis 2009 [Epub ahead of print].
42. Solomon DH, Glynn RJ, Rothman KJ, et al. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum 2008; 59:1097-1104.
43. Goodson NJ, Brookhart AM, Symmons DP, et al. Nonsteroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis 2009; 68:367-372.
44. Becker MC, Wang TH, Wisniewski L, et al., PRECISION Investigators. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal anti-inflammatory agents in patients with arthritis. Am Heart J 2009; 157:606-612.
45. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recom-mendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2009 [Epub ahead of print].
46. Bansback N, Ara R, Ward S, et al. Statin therapy in rheumatoid arthritis: a cost-effectiveness and value-of-information analysis. Pharmacoeconomics 2009; 27:25-37.
47. Toms TE, Panoulas VF, Douglas KM, et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid associated CV risk. Ann Rheum Dis 2009 [Epub ahead of print].
48. Ridker PM, Danielson E, Fonseca FA, et al., JUPITER Study Group. Rosu-vastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207.
49. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008; 336:1475-1482.
50. U.S. Preventive Services Task Force. Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 151:474-482.